Misplaced Pages

#883116

101-498: Before the boom in thymidine use caused by the need for thymidine in the production of the antiretroviral drug azidothymidine (AZT), much of the world's thymidine production came from herring sperm. Thymidine occurs almost exclusively in DNA but it also occurs in the T-loop of tRNA . In its composition, deoxythymidine is a nucleoside composed of deoxyribose (a pentose sugar ) joined to

202-455: A PI / NNRTI / INSTI ("base"). Initial regimens use "first-line" drugs with a high efficacy and low side-effect profile. The US DHHS preferred initial regimens for adults and adolescents in the United States, as of April 2015, are: Both efavirenz and nevirapine showed similar benefits when combined with NRTI respectively. In the case of the protease inhibitor based regimens, ritonavir

303-721: A capsid ), and sometimes covered with a lipid layer (sometimes called an 'envelope'). Viruses cannot reproduce on their own and instead propagate by subjugating a host cell to produce copies of themselves, thus producing the next generation. Researchers working on such " rational drug design " strategies for developing antivirals have tried to attack viruses at every stage of their life cycles. Some species of mushrooms have been found to contain multiple antiviral chemicals with similar synergistic effects. Compounds isolated from fruiting bodies and filtrates of various mushrooms have broad-spectrum antiviral activities, but successful production and availability of such compounds as frontline antiviral

404-563: A 69% increase in the risk of death. In 2015 the START and TEMPRANO studies both showed that patients lived longer if they started antiretrovirals at the time of their diagnosis, rather than waiting for their CD4 counts to drop to a specified level. Other arguments for starting therapy earlier are that people who start therapy later have been shown to have less recovery of their immune systems, and higher CD4 counts are associated with less cancer. The European Medicines Agency (EMA) has recommended

505-437: A greatly expanded knowledge of the genetic and molecular function of organisms, allowing biomedical researchers to understand the structure and function of viruses, major advances in the techniques for finding new drugs, and the pressure placed on the medical profession to deal with the human immunodeficiency virus (HIV), the cause of acquired immunodeficiency syndrome ( AIDS ). The first experimental antivirals were developed in

606-532: A high frequency of mutations. DNA viruses, such as HPV and herpesvirus, hijack host cell replication machinery, which gives them proofreading capabilities during replication. DNA viruses are therefore less error prone, are generally less diverse, and are more slowly evolving than RNA viruses. In both cases, the likelihood of mutations is exacerbated by the speed with which viruses reproduce, which provides more opportunities for mutations to occur in successive replications. Billions of viruses are produced every day during

707-522: A high rate of baseline resistance, resistance testing is recommended before starting treatment; or, if the initiation of treatment is urgent, then a "best guess" treatment regimen should be started, which is then modified on the basis of resistance testing. In the UK, there is 11.8% medium to high-level resistance at baseline to the combination of efavirenz + zidovudine + lamivudine, and 6.4% medium to high level resistance to stavudine + lamivudine + nevirapine . In

808-534: A lasting effect. As a result, the standard of care is to use combinations of antiretroviral drugs. Combinations usually consist of three drugs from at least two different classes. This three drug combination is commonly known as a triple cocktail. Combinations of antiretrovirals are subject to positive and negative synergies , which limits the number of useful combinations. Because of HIV's tendency to mutate, when patients who have started an antiretrovial regimen fail to take it regularly, resistance can develop. On

909-473: A mutation in the CCR5 delta gene which results in a nonfunctional CCR5 co-receptor and in turn, a means of resistance or slow progression of the disease. However, as mentioned previously, this can be overcome if an HIV variant that targets CXCR4 becomes dominant. To prevent fusion of the virus with the host membrane, enfuvirtide can be used. Enfuvirtide is a peptide drug that must be injected and acts by interacting with

1010-412: A range of views on this subject and the decision of whether to commence treatment ultimately rests with the patient and his or her doctor. The US DHHS guidelines (published April 8, 2015) state: The newest WHO guidelines (dated September 30, 2015) now agree and state: Baseline resistance is the presence of resistance mutations in patients who have never been treated before for HIV. In countries with

1111-453: A researcher might target a critical enzyme synthesized by the virus, but not by the patient, that is common across strains, and see what can be done to interfere with its operation. Once targets are identified, candidate drugs can be selected, either from drugs already known to have appropriate effects or by actually designing the candidate at the molecular level with a computer-aided design program. The target proteins can be manufactured in

SECTION 10

#1733086009884

1212-545: A treatment for hepatitis B. Antiviral resistance can be defined by a decreased susceptibility to a drug caused by changes in viral genotypes. In cases of antiviral resistance, drugs have either diminished or no effectiveness against their target virus. The issue inevitably remains a major obstacle to antiviral therapy as it has developed to almost all specific and effective antimicrobials , including antiviral agents. The Centers for Disease Control and Prevention (CDC) inclusively recommends anyone six months and older to get

1313-465: A yearly vaccination to protect them from influenza A viruses (H1N1) and (H3N2) and up to two influenza B viruses (depending on the vaccination). Comprehensive protection starts by ensuring vaccinations are current and complete. However, vaccines are preventative and are not generally used once a patient has been infected with a virus. Additionally, the availability of these vaccines can be limited based on financial or locational reasons which can prevent

1414-409: Is a component of reverse transcriptase that splits the synthesized DNA from the original viral RNA. Another target is integrase , which integrate the synthesized DNA into the host cell genome. Examples of integrase inhibitors include raltegravir , elvitegravir , and dolutegravir . Once a virus genome becomes operational in a host cell, it then generates messenger RNA (mRNA) molecules that direct

1515-483: Is a group of experimental antiviral drugs initially developed at the Massachusetts Institute of Technology . In cell culture, DRACO was reported to have broad-spectrum efficacy against many infectious viruses, including dengue flavivirus , Amapari and Tacaribe arenavirus , Guama bunyavirus , H1N1 influenza and rhinovirus , and was additionally found effective against influenza in vivo in weanling mice. It

1616-403: Is a long way away. Viral life cycles vary in their precise details depending on the type of virus, but they all share a general pattern: One antiviral strategy is to interfere with the ability of a virus to infiltrate a target cell. The virus must go through a sequence of steps to do this, beginning with binding to a specific " receptor " molecule on the surface of the host cell and ending with

1717-663: Is a nucleoside analogue, and is effective against herpesvirus infections. The first antiviral drug to be approved for treating HIV, zidovudine (AZT), is also a nucleoside analogue. An improved knowledge of the action of reverse transcriptase has led to better nucleoside analogues to treat HIV infections. One of these drugs, lamivudine , has been approved to treat hepatitis B, which uses reverse transcriptase as part of its replication process. Researchers have gone further and developed inhibitors that do not look like nucleosides, but can still block reverse transcriptase. Another target being considered for HIV antivirals include RNase H —which

1818-469: Is a set of drugs based on ribozymes , which are enzymes that will cut apart viral RNA or DNA at selected sites. In their natural course, ribozymes are used as part of the viral manufacturing sequence, but these synthetic ribozymes are designed to cut RNA and DNA at sites that will disable them. A ribozyme antiviral to deal with hepatitis C has been suggested, and ribozyme antivirals are being developed to deal with HIV. An interesting variation of this idea

1919-492: Is also important, with a planned Caesarian section having a lower risk than vaginal delivery or emergency Caesarian section. HIV can also be detected in breast milk of infected mothers and transmitted through breast feeding. The WHO balances the low risk of transmission through breast feeding from women who are on ART with the benefits of breastfeeding against diarrhea, pneumonia and malnutrition. It also strongly recommends that breastfeeding infants receive prophylactic ART. In

2020-426: Is an antiviral drug . Telbivudine (β- L -2′-deoxythymidine, LdT) is the unmodified "unnatural" L - enantiomer of thymidine that was used in the treatment of chronic hepatitis B . During growth of bacteriophage T4 , an excess of thymidine availability increases mutation . A deficiency of thymidine during growth also increases mutation. A thymidylate auxotroph of the diploid yeast Saccharomyces cerevisiae

2121-416: Is commonly used in cell proliferation assays. The thymidine is incorporated into dividing cells and the level of this incorporation, measured using a liquid scintillation counter , is proportional to the amount of cell proliferation. For example, lymphocyte proliferation can be measured this way in lymphoproliferative disorders . Bromodeoxyuridine (BrdU) is another thymidine analog that is often used for

SECTION 20

#1733086009884

2222-451: Is complicated by the fact that many children who are born to mothers with HIV are given a single dose of nevirapine (an NNRTI) at the time of birth to prevent transmission. If this fails it can lead to NNRTI resistance. Also, a large study in Africa and India found that a PI based regimen was superior to an NNRTI based regimen in children less than 3 years who had never been exposed to NNRTIs in

2323-419: Is currently widespread in seasonal H1N1 strains. The genetic makeup of viruses is constantly changing, which can cause a virus to become resistant to currently available treatments. Viruses can become resistant through spontaneous or intermittent mechanisms throughout the course of an antiviral treatment. Immunocompromised patients, more often than immunocompetent patients, hospitalized with pneumonia are at

2424-437: Is indeed within reach." In the same paper, he noted that an estimated 700,000 lives were saved in 2010 alone by antiretroviral therapy. As another commentary noted, "Rather than dealing with acute and potentially life-threatening complications, clinicians are now confronted with managing a chronic disease that in the absence of a cure will persist for many decades." The United States Department of Health and Human Services and

2525-454: Is intended for maintenance treatment of adults who have undetectable HIV levels in the blood (viral load less than 50 copies/ml) with their current ARV treatment, and when the virus has not developed resistance to certain class of anti-HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs) and integrase strand transfer inhibitors (INIs). A separate argument for starting antiretroviral therapy that has gained more prominence

2626-536: Is intrinsically resistant to NNRTIs. Integrase inhibitors (also known as integrase nuclear strand transfer inhibitors or INSTIs) inhibit the viral enzyme integrase , which is responsible for integration of viral DNA into the DNA of the infected cell. There are several integrase inhibitors under clinical trial, and raltegravir became the first to receive FDA approval in October 2007. Raltegravir has two metal binding groups that compete for substrate with two Mg ions at

2727-555: Is its effect on HIV transmission. ART reduces the amount of virus in the blood and genital secretions. This has been shown to lead to dramatically reduced transmission of HIV when one partner with a suppressed viral load (<50 copies/ml) has sex with a partner who is HIV negative. In clinical trial HPTN 052 , 1763 serodiscordant heterosexual couples in nine countries were planned to be followed for at least 10 years, with both groups receiving education on preventing HIV transmission and condoms, but only one group getting ART. The study

2828-429: Is no meaningful difference between abacavir-containing regimens and other NRTI-containing regimens. The evidence is of low to moderate quality and therefore it is likely that future research may change these findings. The goals of treatment for pregnant women include the same benefits to the mother as in other infected adults as well as prevention of transmission to her child. The risk of transmission from mother to child

2929-513: Is partly trial and error, it can be a relatively slow process until an adequate molecule is produced. A very early stage of viral infection is viral entry , when the virus attaches to and enters the host cell. A number of "entry-inhibiting" or "entry-blocking" drugs are being developed to fight HIV. HIV most heavily targets a specific type of lymphocyte known as "helper T cells", and identifies these target cells through T-cell surface receptors designated " CD4 " and " CCR5 ". Attempts to interfere with

3030-399: Is proportional to the plasma viral load of the mother. Untreated mothers with a viral load >100,000 copies/ml have a transmission risk of over 50%. The risk when viral loads are < 1000 copies/ml are less than 1%. ART for mothers both before and during delivery and to mothers and infants after delivery are recommended to substantially reduce the risk of transmission. The mode of delivery

3131-550: Is similar in most strains of rhinoviruses and enteroviruses , which can cause diarrhea, meningitis , conjunctivitis , and encephalitis . Some scientists are making the case that a vaccine against rhinoviruses, the predominant cause of the common cold, is achievable. Vaccines that combine dozens of varieties of rhinovirus at once are effective in stimulating antiviral antibodies in mice and monkeys, researchers reported in Nature Communications in 2016. Rhinoviruses are

Thymidine - Misplaced Pages Continue

3232-412: Is that it potentially may not only prevent the spread of the virus within an infected individual but also the spread from an infected to an uninfected individual. One possible advantage of the therapeutic approach of blocking viral entry (as opposed to the currently dominant approach of viral enzyme inhibition) is that it may prove more difficult for the virus to develop resistance to this therapy than for

3333-406: Is the use of genetically modified cells that can produce custom-tailored ribozymes. This is part of a broader effort to create genetically modified cells that can be injected into a host to attack pathogens by generating specialized proteins that block viral replication at various phases of the viral life cycle. Interference with post translational modifications or with targeting of viral proteins in

3434-423: Is to identify viral proteins, or parts of proteins, that can be disabled. These "targets" should generally be as unlike any proteins or parts of proteins in humans as possible, to reduce the likelihood of side effects and toxicity. The targets should also be common across many strains of a virus, or even among different species of virus in the same family, so a single drug will have broad effectiveness. For example,

3535-453: Is to synthesize antibodies , protein molecules that can bind to a pathogen and mark it for attack by other elements of the immune system. Once researchers identify a particular target on the pathogen, they can synthesize quantities of identical "monoclonal" antibodies to link up that target. A monoclonal drug is now being sold to help fight respiratory syncytial virus in babies, and antibodies purified from infected individuals are also used as

3636-555: Is to target the processes that synthesize virus components after a virus invades a cell. One way of doing this is to develop nucleotide or nucleoside analogues that look like the building blocks of RNA or DNA , but deactivate the enzymes that synthesize the RNA or DNA once the analogue is incorporated. This approach is more commonly associated with the inhibition of reverse transcriptase (RNA to DNA) than with "normal" transcriptase (DNA to RNA). The first successful antiviral, aciclovir ,

3737-446: Is used at low doses to inhibit cytochrome p450 enzymes and "boost" the levels of other protease inhibitors, rather than for its direct antiviral effect. This boosting effect allows them to be taken less frequently throughout the day. Cobicistat is used with elvitegravir for a similar effect but does not have any direct antiviral effect itself. The WHO preferred initial regimen for adults and adolescents as of June 30, 2013, is: In

3838-408: Is very high. Deoxythymidine is non-toxic and is part of one of the four nucleosides in DNA. It is a naturally occurring compound that exists in all living organisms and DNA viruses. Instead of thymidine, RNA contains uridine ( uracil joined to ribose ). Uracil is chemically very similar to thymine, which is also known as 5-methyluracil. Since thymine nucleotides are precursors of DNA (but not RNA),

3939-466: The HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy ( HAART ). HAART decreases the patient's total burden of HIV, maintains function of the immune system , and prevents opportunistic infections that often lead to death. HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as

4040-479: The World Health Organization (WHO) recommend offering antiretroviral treatment to all patients with HIV . Because of the complexity of selecting and following a regimen, the potential for side effects, and the importance of taking medications regularly to prevent viral resistance , such organizations emphasize the importance of involving patients in therapy choices and recommend analyzing the risks and

4141-405: The hepatitis B and C viruses, and influenza A and B viruses. Viruses use the host's cells to replicate and this makes it difficult to find targets for the drug that would interfere with the virus without also harming the host organism's cells. Moreover, the major difficulty in developing vaccines and antiviral drugs is due to viral variation. The emergence of antivirals is the product of

Thymidine - Misplaced Pages Continue

4242-499: The pyrimidine base thymine . Deoxythymidine can be phosphorylated with one, two or three phosphoric acid groups, creating dTMP ( d eoxy t hymidine m ono p hosphate), dTDP , or dTTP (for the d i- and t ri- phosphates, respectively). It exists in solid form as small white crystals or white crystalline powder . It has a molecular weight of 242.229 Da and a melting point of 185  °C . The stability of deoxythymidine under standard temperature and pressure (STP)

4343-448: The 1960s, mostly to deal with herpes viruses , and were found using traditional trial-and-error drug discovery methods. Researchers grew cultures of cells and infected them with the target virus. They then introduced into the cultures chemicals which they thought might inhibit viral activity and observed whether the level of virus in the cultures rose or fell. Chemicals that seemed to have an effect were selected for closer study. This

4444-580: The HIV-positive partner maintains an undetectable viral load. Treatment has been so successful that in many parts of the world, HIV has become a chronic condition in which progression to AIDS is increasingly rare. Anthony Fauci , former head of the United States National Institute of Allergy and Infectious Diseases , has written, "With collective and resolute action now and a steadfast commitment for years to come, an AIDS-free generation

4545-462: The N-terminal heptad repeat of gp41 of HIV to form an inactive hetero six-helix bundle, therefore preventing infection of host cells. Nucleoside reverse-transcriptase inhibitors (NRTI) and nucleotide reverse-transcriptase inhibitors (NtRTI) are nucleoside and nucleotide analogues which inhibit reverse transcription. HIV is an RNA virus, so it can not be integrated into the DNA in the nucleus of

4646-561: The National Institute of Allergy and Infectious Diseases began recruiting patients for a trial examining the effects of a three drug combination of the protease inhibitor indinavir and two nucleoside analogs, illustrating the substantial benefit of combining two NRTIs with a new class of antiretrovirals, protease inhibitors , namely indinavir . Later that year David Ho became an advocate of this "hit hard, hit early" approach with aggressive treatment with multiple antiretrovirals early in

4747-527: The PARTNER study, which ran from 2010 to 2014, enrolled 1166 serodiscordant couples (where one partner is HIV positive and the other is negative) in a study that found that the estimated rate of transmission through any condomless sex with the HIV-positive partner taking ART with an HIV load less than 200 copies/ml was zero. In summary, as the WHO HIV treatment guidelines state, "The ARV regimens now available, even in

4848-532: The US, 10.8% of one cohort of patients who had never been on ART before had at least one resistance mutation in 2005. Various surveys in different parts of the world have shown increasing or stable rates of baseline resistance as the era of effective HIV therapy continues. With baseline resistance testing, a combination of antiretrovirals that are likely to be effective can be customized for each patient. Most HAART regimens consist of three drugs: Two NRTIs ("backbone")+

4949-627: The US, the DHHS recommends against women with HIV breastfeeding. Antiviral drug Antiviral drugs are a class of medication used for treating viral infections . Most antivirals target specific viruses , while a broad-spectrum antiviral is effective against a wide range of viruses. Antiviral drugs are a class of antimicrobials , a larger group which also includes antibiotic (also termed antibacterial), antifungal and antiparasitic drugs, or antiviral drugs based on monoclonal antibodies . Most antivirals are considered relatively harmless to

5050-704: The United States there are both the International AIDS Society-USA (IAS-USA) (a 501(c)(3) not-for-profit organization in the US) as well as the US government's Department of Health and Human Services guidelines. In Europe there are the European AIDS Clinical Society guidelines. For resource limited countries, most national guidelines closely follow the World Health Organization (WHO) guidelines. The guidelines use new criteria to consider starting HAART, as described below. However, there remain

5151-448: The binding of HIV with the CD4 receptor have failed to stop HIV from infecting helper T cells, but research continues on trying to interfere with the binding of HIV to the CCR5 receptor in hopes that it will be more effective. HIV infects a cell through fusion with the cell membrane, which requires two different cellular molecular participants, CD4 and a chemokine receptor (differing depending on

SECTION 50

#1733086009884

5252-603: The binding of these antisense segments to these target sections blocks the operation of those genomes. A phosphorothioate antisense drug named fomivirsen has been introduced, used to treat opportunistic eye infections in AIDS patients caused by cytomegalovirus , and other antisense antivirals are in development. An antisense structural type that has proven especially valuable in research is morpholino antisense. Morpholino oligos have been used to experimentally suppress many viral types: Yet another antiviral technique inspired by genomics

5353-424: The cascade, and cleave a variety of cellular proteins, thereby killing the cell. Rifampicin acts at the assembly phase. The final stage in the life cycle of a virus is the release of completed viruses from the host cell, and this step has also been targeted by antiviral drug developers. Two drugs named zanamivir (Relenza) and oseltamivir (Tamiflu) that have been recently introduced to treat influenza prevent

5454-632: The cell is also possible. Some viruses include an enzyme known as a protease that cuts viral protein chains apart so they can be assembled into their final configuration. HIV includes a protease, and so considerable research has been performed to find " protease inhibitors " to attack HIV at that phase of its life cycle. Protease inhibitors became available in the 1990s and have proven effective, though they can have unusual side effects, for example causing fat to build up in unusual places. Improved protease inhibitors are now in development. Protease inhibitors have also been seen in nature. A protease inhibitor

5555-402: The cell type). Approaches to blocking this virus/cell fusion have shown some promise in preventing entry of the virus into a cell. At least one of these entry inhibitors—a biomimetic peptide called Enfuvirtide , or the brand name Fuzeon—has received FDA approval and has been in use for some time. Potentially, one of the benefits from the use of an effective entry-blocking or entry-inhibiting agent

5656-458: The course of an infection, with each replication giving another chance for mutations that encode for resistance to occur. Multiple strains of one virus can be present in the body at one time, and some of these strains may contain mutations that cause antiviral resistance. This effect, called the quasispecies model , results in immense variation in any given sample of virus, and gives the opportunity for natural selection to favor viral strains with

5757-412: The course of the infection. Later reviews in the late 90s and early 2000s noted that this approach of "hit hard, hit early" ran significant risks of increasing side effects and development of multidrug resistance, and this approach was largely abandoned. The only consensus was on treating patients with advanced immunosuppression (CD4 counts less than 350/μL). Treatment with antiretrovirals was expensive at

5858-427: The detection of proliferating cells in living tissues. 5-Ethynyl-2´-deoxyuridine (EdU) is a thymidine analog which is incorporated into the DNA of dividing cells and is used to assay DNA synthesis in cell culture or living tissues. It can be visualized by covalently binding a fluorescent azide using click chemistry , which is less harsh than the conditions used to expose the epitope for BrdU antibodies. Edoxudine

5959-585: The development of multi-drug resistant mutations. In contrast, antiretroviral combination therapy defends against resistance by creating multiple obstacles to HIV replication. This keeps the number of viral copies low and reduces the possibility of a superior mutation. If a mutation that conveys resistance to one of the drugs arises, the other drugs continue to suppress reproduction of that mutation. With rare exceptions, no individual antiretroviral drug has been demonstrated to suppress an HIV infection for long; these agents must be taken in combinations in order to have

6060-470: The drug resistant strains to become dominant. This in turn makes it harder to treat the infected individual as well as anyone else they infect. One trial showed higher rates of opportunistic infections, cancers, heart attacks and death in patients who periodically interrupted their ART. There are several treatment guidelines for HIV-1 infected adults in the developed world (that is, those countries with access to all or most therapies and laboratory tests). In

6161-410: The ease with which they can be taken, which in turn increases the consistency with which medication is taken ( adherence ), and thus their effectiveness over the long-term. Although antiretroviral therapy has helped to improve the quality of life of people living with HIV, there is still a need to explore other ways to further address the disease burden. One such potential strategy that was investigated

SECTION 60

#1733086009884

6262-504: The effectiveness of herd immunity, making effective antivirals a necessity. The three FDA-approved neuraminidase antiviral flu drugs available in the United States, recommended by the CDC, include: oseltamivir (Tamiflu), zanamivir (Relenza), and peramivir (Rapivab). Influenza antiviral resistance often results from changes occurring in neuraminidase and hemagglutinin proteins on the viral surface. Currently, neuraminidase inhibitors (NAIs) are

6363-400: The enzyme; NNRTIs act as non-competitive inhibitors of reverse transcriptase . NNRTIs affect the handling of substrate (nucleotides) by reverse transcriptase by binding near the active site. NNRTIs can be further classified into 1st generation and 2nd generation NNRTIs. 1st generation NNRTIs include nevirapine and efavirenz . 2nd generation NNRTIs are etravirine and rilpivirine . HIV-2

6464-580: The first six months after infection HIV viral loads tend to be elevated and people are more often symptomatic than in later latent phases of HIV disease. There may be special benefits to starting antiretroviral therapy early during this acute phase, including lowering the viral "set-point" or baseline viral load, reduce the mutation rate of the virus, and reduce the size of the viral reservoir (See section below on viral reservoirs ). The SPARTAC trial compared 48 weeks of ART vs 12 weeks vs no treatment in acute HIV infection and found that 48 weeks of treatment delayed

6565-501: The granting of marketing authorizations for two new antiretroviral (ARV) medicines, rilpivirine (Rekambys) and cabotegravir (Vocabria), to be used together for the treatment of people with human immunodeficiency virus type 1 (HIV-1) infection. The two medicines are the first ARVs that come in a long-acting injectable formulation. This means that instead of daily pills, people receive intramuscular injections monthly or every two months. The combination of Rekambys and Vocabria injection

6666-577: The highest risk of developing oseltamivir resistance during treatment. Subsequent to exposure to someone else with the flu, those who received oseltamivir for "post-exposure prophylaxis" are also at higher risk of resistance. The mechanisms for antiviral resistance development depend on the type of virus in question. RNA viruses such as hepatitis C and influenza A have high error rates during genome replication because RNA polymerases lack proofreading activity. RNA viruses also have small genome sizes that are typically less than 30 kb, which allow them to sustain

6767-495: The host cell by blocking one of several targets. Maraviroc , enfuvirtide and Ibalizumab are available agents in this class. Maraviroc works by targeting CCR5 , a co-receptor located on human helper T-cells. Caution should be used when administering this drug, however, due to a possible shift in tropism which allows HIV to target an alternative co-receptor such as CXCR4 . Ibalizumab is effective against both CCR5 and CXCR4 tropic HIV viruses. In rare cases, individuals may have

6868-406: The host, and therefore can be used to treat infections . They should be distinguished from virucides , which are not medication but deactivate or destroy virus particles, either inside or outside the body. Natural virucides are produced by some plants such as eucalyptus and Australian tea trees . Most of the antiviral drugs now available are designed to help deal with HIV , herpes viruses ,

6969-742: The human cell unless it is first "reverse" transcribed into DNA. Since the conversion of RNA to DNA is not naturally done in the mammalian cell, it is performed by a viral protein, reverse transcriptase , which makes it a selective target for inhibition. NRTIs are chain terminators. Once NRTIs are incorporated into the DNA chain, their lack of a 3' OH group prevents the subsequent incorporation of other nucleosides. Both NRTIs and NtRTIs act as competitive substrate inhibitors . Examples of NRTIs include zidovudine , abacavir , lamivudine , emtricitabine , and of NtRTIs – tenofovir and adefovir . Non-nucleoside reverse-transcriptase inhibitors (NNRTI) inhibit reverse transcriptase by binding to an allosteric site of

7070-410: The immune system to attack a range of pathogens. One of the best-known of this class of drugs are interferons , which inhibit viral synthesis in infected cells. One form of human interferon named "interferon alpha" is well-established as part of the standard treatment for hepatitis B and C, and other interferons are also being investigated as treatments for various diseases. A more specific approach

7171-429: The lab for testing with candidate treatments by inserting the gene that synthesizes the target protein into bacteria or other kinds of cells. The cells are then cultured for mass production of the protein, which can then be exposed to various treatment candidates and evaluated with "rapid screening" technologies. Viruses consist of a genome and sometimes a few enzymes stored in a capsule made of protein (called

7272-422: The metal binding site of integrase. As of early 2022, four other clinically approved integrase inhibitors are elvitegravir , dolutegravir , bictegravir , and cabotegravir . Protease inhibitors block the viral protease enzyme necessary to produce mature virions upon budding from the host membrane. Particularly, these drugs prevent the cleavage of gag and gag/pol precursor proteins. Virus particles produced in

7373-465: The most common cause of the common cold; other viruses such as respiratory syncytial virus , parainfluenza virus and adenoviruses can cause them too. Rhinoviruses also exacerbate asthma attacks. Although rhinoviruses come in many varieties, they do not drift to the same degree that influenza viruses do. A mixture of 50 inactivated rhinovirus types should be able to stimulate neutralizing antibodies against all of them to some degree. A second approach

7474-461: The most frequently prescribed antivirals because they are effective against both influenza A and B. However, antiviral resistance is known to develop if mutations to the neuraminidase proteins prevent NAI binding. This was seen in the H257Y mutation, which was responsible for oseltamivir resistance to H1N1 strains in 2009. The inability of NA inhibitors to bind to the virus allowed this strain of virus with

7575-453: The other hand, patients who take their medications regularly can stay on one regimen without developing resistance. This greatly increases life expectancy and leaves more drugs available to the individual should the need arise. In 2000 drug companies have worked together to combine these complex regimens into single-pill fixed-dose combinations . More than 20 antiretroviral fixed-dose combinations have been developed. This greatly increases

7676-780: The past. Thus the WHO recommends PI based regimens for children less than 3. The WHO recommends for children less than 3 years: and for children 3 years to less than 10 years and adolescents <35 kilograms: US DHHS guidelines are similar but include PI based options for children > 3 years old. A systematic review assessed the effects and safety of abacavir-containing regimens as first-line therapy for children between 1 month and 18 years of age when compared to regimens with other NRTIs. This review included two trials and two observational studies with almost eleven thousand HIV infected children and adolescents. They measured virologic suppression, death and adverse events. The authors found that there

7777-465: The phase of the retrovirus life-cycle that the drug inhibits. Typical combinations include two nucleoside reverse-transcriptase inhibitors (NRTI) as a "backbone" along with one non-nucleoside reverse-transcriptase inhibitor (NNRTI), protease inhibitor (PI) or integrase inhibitors (also known as integrase nuclear strand transfer inhibitors or INSTIs) as a "base". Entry inhibitors (or fusion inhibitors) interfere with binding, fusion and entry of HIV-1 to

7878-402: The poorest countries, are safer, simpler, more effective and more affordable than ever before." There is a consensus among experts that, once initiated, antiretroviral therapy should never be stopped. This is because the selection pressure of incomplete suppression of viral replication in the presence of drug therapy causes the more drug sensitive strains to be selectively inhibited. This allows

7979-472: The potential benefits. The WHO has defined health as more than the absence of disease. For this reason, many researchers have dedicated their work to better understanding the effects of HIV-related stigma, the barriers it creates for treatment interventions, and the ways in which those barriers can be circumvented. There are six classes of drugs, which are usually used in combination, to treat HIV infection. Antiretroviral (ARV) drugs are broadly classified by

8080-493: The prefix "deoxy" is often left out, i.e., deoxythymidine is often just called thymidine. Thymidine is listed as a chemical teratogen . Iododeoxyuridine is a radiosensitizer and increases the amount of DNA damage received from ionizing radiation. Azidothymidine (AZT) – used in the treatment of HIV infection. AZT inhibits the process of reverse transcription , a critical step in the viral life cycle . Radiolabeled thymidine (TdR), such as tritiated thymidine (H-TdR),

8181-412: The presence of protease inhibitors are defective and mostly non-infectious. Examples of HIV protease inhibitors are lopinavir , indinavir , nelfinavir , amprenavir and ritonavir . Darunavir and atazanavir are recommended as first line therapy choices. Maturation inhibitors have a similar effect by binding to gag, but development of two experimental drugs in this class, bevirimat and vivecon ,

8282-426: The release of viral particles by blocking a molecule named neuraminidase that is found on the surface of flu viruses, and also seems to be constant across a wide range of flu strains. Rather than attacking viruses directly, a second category of tactics for fighting viruses involves encouraging the body's immune system to attack them. Some antivirals of this sort do not focus on a specific pathogen, instead stimulating

8383-502: The resistance mutation to spread due to natural selection. Furthermore, a study published in 2009 in Nature Biotechnology emphasized the urgent need for augmentation of oseltamivir stockpiles with additional antiviral drugs including zanamivir. This finding was based on a performance evaluation of these drugs supposing the 2009 H1N1 'Swine Flu' neuraminidase (NA) were to acquire the oseltamivir-resistance (His274Tyr) mutation, which

8484-636: The risk of HIV transmission from a person living with HIV who has been undetectable for a minimum of six months is negligible to non-existent, with negligible being defined as "so small or unimportant to be not worth considering". The Chair of the British HIV Association (BHIVA), Chloe Orkin , stated in July 2017 that 'there should be no doubt about the clear and simple message that a person with sustained, undetectable levels of HIV virus in their blood cannot transmit HIV to their sexual partners.' Furthermore,

8585-756: The risks of HIV treatment. Therapy during acute infection carries a grade BII recommendation from the US DHHS. HIV can be especially harmful to infants and children, with one study in Africa showing that 52% of untreated children born with HIV had died by age 2. By five years old, the risk of disease and death from HIV starts to approach that of young adults. The WHO recommends treating all children less than 5 years old, and starting all children older than 5 with stage 3 or 4 disease or CD4 <500 cells/ml. DHHS guidelines are more complicated but recommend starting all children less than 12 months old and children of any age who have symptoms. As for which antiretrovirals to use, this

8686-488: The synthesis of viral proteins. Production of mRNA is initiated by proteins known as transcription factors . Several antivirals are now being designed to block attachment of transcription factors to viral DNA. Genomics has not only helped find targets for many antivirals, it has provided the basis for an entirely new type of drug, based on "antisense" molecules. These are segments of DNA or RNA that are designed as complementary molecule to critical sections of viral genomes, and

8787-610: The time to decline in CD4 count below 350 cells per ml by 65 weeks and kept viral loads significantly lower even after treatment was stopped. Since viral loads are usually very high during acute infection, this period carries an estimated 26 times higher risk of transmission. By treating acutely infected patients, it is presumed that it could have a significant impact on decreasing overall HIV transmission rates since lower viral loads are associated with lower risk of transmission (See section on treatment as prevention ). However an overall benefit has not been proven and has to be balanced with

8888-405: The time, ranging from $ 10,000 to $ 15,000 a year. The timing of when to start therapy has continued to be a core controversy within the medical community, though recent studies have led to more clarity. The NA-ACCORD study observed patients who started antiretroviral therapy either at a CD4 count of less than 500 versus less than 350 and showed that patients who started ART at lower CD4 counts had

8989-557: The use of interleukin 2 as an add-on treatment to antiretroviral therapy for adults with HIV. Antiretroviral drug treatment guidelines have changed over time. Before 1987, no antiretroviral drugs were available and treatment consisted of treating complications from opportunistic infections and malignancies. After antiretroviral medications were introduced, most clinicians agreed that HIV positive patients with low CD4 counts should be treated, but no consensus formed as to whether to treat patients with high CD4 counts. In April 1995, Merck and

9090-413: The virus "uncoating" inside the cell and releasing its contents. Viruses that have a lipid envelope must also fuse their envelope with the target cell, or with a vesicle that transports them into the cell before they can uncoat. This stage of viral replication can be inhibited in two ways: This strategy of designing drugs can be very expensive, and since the process of generating anti-idiotypic antibodies

9191-408: The virus to mutate or evolve its enzymatic protocols. Inhibitors of uncoating have also been investigated. Amantadine and rimantadine have been introduced to combat influenza. These agents act on penetration and uncoating. Pleconaril works against rhinoviruses , which cause the common cold , by blocking a pocket on the surface of the virus that controls the uncoating process. This pocket

9292-410: The virus to mutate very rapidly, resulting in a high genetic variability. Most of the mutations either are inferior to the parent virus (often lacking the ability to reproduce at all) or convey no advantage, but some of them have a natural selection superiority to their parent and can enable them to slip past defenses such as the human immune system and antiretroviral drugs. The more active copies of

9393-449: The virus, the greater the possibility that one resistant to antiretroviral drugs will be made. When antiretroviral drugs are used improperly, multi-drug resistant strains can become the dominant genotypes very rapidly. In the era before multiple drug classes were available (pre-1997), the reverse-transcriptase inhibitors zidovudine , didanosine , zalcitabine , stavudine , and lamivudine were used serially or in combination leading to

9494-486: Was a very time-consuming, hit-or-miss procedure, and in the absence of a good knowledge of how the target virus worked, it was not efficient in discovering effective antivirals which had few side effects . Only in the 1980s, when the full genetic sequences of viruses began to be unraveled, did researchers begin to learn how viruses worked in detail, and exactly what chemicals were needed to thwart their reproductive cycle. The general idea behind modern antiviral drug design

9595-498: Was grown under conditions in which thymidyate levels varied from excess to depletion. High levels of thymidylate were observed to be mutagenic and recombinogenic, whereas starvation for thymidylate was recombinogenic but only slightly mutagenic. Antiretroviral drug The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection . There are several classes of antiretroviral agents that act on different stages of

9696-532: Was halted in 2010. Resistance to some protease inhibitors is high. Second generation drugs have been developed that are effective against otherwise resistant HIV variants. The life cycle of HIV can be as short as about 1.5 days from viral entry into a cell, through replication, assembly, and release of additional viruses, to infection of other cells. HIV lacks proofreading enzymes to correct errors made when it converts its RNA into DNA via reverse transcription . Its short life-cycle and high error rate cause

9797-484: Was isolated from the shiitake mushroom ( Lentinus edodes ). The presence of this may explain the Shiitake mushrooms' noted antiviral activity in vitro . Most viruses produce long dsRNA helices during transcription and replication. In contrast, uninfected mammalian cells generally produce dsRNA helices of fewer than 24 base pairs during transcription. DRACO ( double-stranded RNA activated caspase oligomerizer )

9898-689: Was likely to be suppressed. Pre-exposure prophylaxis (PrEP) provides HIV-negative individuals with medication—in conjunction with safer-sex education and regular HIV/STI screenings—in order to reduce the risk of acquiring HIV. In 2011, the journal Science gave the Breakthrough of the Year award to treatment as prevention. In July 2016 a consensus document was created by the Prevention Access Campaign which has been endorsed by over 400 organisations in 58 countries. The consensus document states that

9999-402: Was reported to induce rapid apoptosis selectively in virus-infected mammalian cells, while leaving uninfected cells unharmed. DRACO effects cell death via one of the last steps in the apoptosis pathway in which complexes containing intracellular apoptosis signalling molecules simultaneously bind multiple procaspases . The procaspases transactivate via cleavage, activate additional caspases in

10100-412: Was stopped early (after 1.7 years) for ethical reasons when it became clear that antiviral treatment provided significant protection. Of the 28 couples where cross-infection had occurred, all but one had taken place in the control group , consistent with a 96% reduction in risk of transmission while on ART. The single transmission in the experimental group occurred early after starting ART before viral load

10201-517: Was to add interleukin 2 as an adjunct to antiretroviral therapy for adults with HIV. A Cochrane review included 25 randomized controlled trials that were conducted across six countries. The researchers found that interleukin 2 increases the CD4 immune cells, but does not make a difference in terms of death and incidence of other infections. Furthermore, there is probably an increase in side-effects with interleukin 2. The findings of this review do not support

#883116